Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2012

01-04-2012 | Original Article

Emu Oil Increases Colonic Crypt Depth in a Rat Model of Ulcerative Colitis

Authors: Suzanne M. Abimosleh, Ruth J. Lindsay, Ross N. Butler, Adrian G. Cummins, Gordon S. Howarth

Published in: Digestive Diseases and Sciences | Issue 4/2012

Login to get access

Abstract

Background

Current treatments for the inflammatory bowel diseases, encompassing Crohn’s disease and ulcerative colitis, are variably effective. Emu oil, extracted from emu fat, predominantly comprises fatty acids, with purported claims of anti-inflammatory properties.

Aim

We evaluated emu oil for its potential to ameliorate dextran sulphate sodium (DSS)-induced colitis in rats.

Methods

Male Sprague–Dawley Rats were allocated to treatment groups (n = 8). Groups 1 and 2 consumed water and were gavaged (1 ml) daily with water (group 1) or emu oil (group 2) from days 0 to 10. Groups 3–6 ingested 2% DSS in the drinking water from days 5 to 10 and were gavaged from days 0 to 10 with water (group 3), 0.5 ml emu oil (group 4) or 1 ml emu oil (group 5). Group 6 received 1 ml emu oil after commencing DSS treatment (days 6–10). Disease activity index, metabolic parameters, 13C-sucrose breath test, and histological colonic damage severity and crypt depth were assessed.

Results

Emu oil in DSS-treated rats reduced colonic damage severity compared to DSS-controls (up to threefold; P < 0.001). In DSS-treated rats, crypts in the proximal colon were lengthened by 0.5 ml emu oil (373 ± 18 μm), compared with DSS-controls (302 ± 8 μm); whilst in the distal colon (DSS control: 271 ± 17 μm), crypt depth was greater following 0.5 ml emu oil (352 ± 22 μm) and 1 ml emu oil (341 ± 9 μm) and also when emu oil was administered post-DSS commencement (Group 6: 409 ± 16 μm; P < 0.05). Emu oil did not significantly affect other parameters of colonic architecture.

Conclusions

Emu oil improved tissue damage associated with colitis, suggesting its potential as a unique formulation to augment conventional treatment approaches for IBD.
Literature
1.
go back to reference Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79–94.PubMedCrossRef Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79–94.PubMedCrossRef
2.
go back to reference Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205.PubMedCrossRef Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205.PubMedCrossRef
3.
go back to reference Boismenu R, Chen Y. Insights from mouse models of colitis. J Leukoc Biol. 2000;67:267–278.PubMed Boismenu R, Chen Y. Insights from mouse models of colitis. J Leukoc Biol. 2000;67:267–278.PubMed
5.
go back to reference Camuesco D, Galvez J, Nieto A, et al. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with dss-induced colitis. J Nutr. 2005;135:687–694.PubMed Camuesco D, Galvez J, Nieto A, et al. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with dss-induced colitis. J Nutr. 2005;135:687–694.PubMed
6.
go back to reference Tenikoff D, Murphy KJ, Le M, Howe PR, Howarth GS. Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease. J Gastroenterol. 2005;40:361–365.PubMedCrossRef Tenikoff D, Murphy KJ, Le M, Howe PR, Howarth GS. Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease. J Gastroenterol. 2005;40:361–365.PubMedCrossRef
7.
go back to reference Whitehouse MW, Turner AG, Davis CK, Roberts MS. Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine. Inflammopharmacol. 1998;6:1–8.CrossRef Whitehouse MW, Turner AG, Davis CK, Roberts MS. Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine. Inflammopharmacol. 1998;6:1–8.CrossRef
8.
go back to reference Snowden JM, Whitehouse MW. Anti-inflammatory activity of emu oils in rats. Inflammopharmacol. 1997;5:127–132.CrossRef Snowden JM, Whitehouse MW. Anti-inflammatory activity of emu oils in rats. Inflammopharmacol. 1997;5:127–132.CrossRef
9.
go back to reference Beckerbauer LM, Thiel-Cooper R, Ahn DU, Sell JL, Parrish FC Jr, Beitz DC. Influence of two dietary fats on the composition of emu oil and meat. Poult Sci. 2001;80:187–194.PubMed Beckerbauer LM, Thiel-Cooper R, Ahn DU, Sell JL, Parrish FC Jr, Beitz DC. Influence of two dietary fats on the composition of emu oil and meat. Poult Sci. 2001;80:187–194.PubMed
10.
go back to reference Brown MA, Craig-Schmidt MC, Smith PC. Fatty acid composition of emu. Inform (Silver Spring, Md). 1995;6:470. Brown MA, Craig-Schmidt MC, Smith PC. Fatty acid composition of emu. Inform (Silver Spring, Md). 1995;6:470.
11.
go back to reference Howarth GS, Lindsay RJ, Butler RN, Geier MS. Can emu oil ameliorate inflammatory disorders affecting the gastrointestinal system? Aust J Exp Agric. 2008;48:1276–1279.CrossRef Howarth GS, Lindsay RJ, Butler RN, Geier MS. Can emu oil ameliorate inflammatory disorders affecting the gastrointestinal system? Aust J Exp Agric. 2008;48:1276–1279.CrossRef
12.
go back to reference Yoganathan S, Nicolosi R, Wilson T, et al. Antagonism of croton oil inflammation by topical emu oil in cd-1 mice. Lipids. 2003;38:603–607.PubMedCrossRef Yoganathan S, Nicolosi R, Wilson T, et al. Antagonism of croton oil inflammation by topical emu oil in cd-1 mice. Lipids. 2003;38:603–607.PubMedCrossRef
13.
go back to reference James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71:343S–348S.PubMed James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71:343S–348S.PubMed
14.
go back to reference Calder PC. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83:1505S–1519S.PubMed Calder PC. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83:1505S–1519S.PubMed
15.
go back to reference Lopez A, Sims DE, Ablett RF, et al. Effect of emu oil on auricular inflammation induced with croton oil in mice. Am J Vet Res. 1999;60:1558–1561.PubMed Lopez A, Sims DE, Ablett RF, et al. Effect of emu oil on auricular inflammation induced with croton oil in mice. Am J Vet Res. 1999;60:1558–1561.PubMed
16.
go back to reference Qiu XW, Wang JH, Fang XW, Gong ZY, Li ZQ, Yi ZH. Anti-inflammatory activity and healing-promoting effects of topical application of emu oil on wound in scalded rats. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:407–410.PubMed Qiu XW, Wang JH, Fang XW, Gong ZY, Li ZQ, Yi ZH. Anti-inflammatory activity and healing-promoting effects of topical application of emu oil on wound in scalded rats. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:407–410.PubMed
17.
go back to reference Lindsay RJ, Geier MS, Yazbeck R, Butler RN, Howarth GS. Orally administered emu oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis. Br J Nutr. 2010;104:513–519.PubMedCrossRef Lindsay RJ, Geier MS, Yazbeck R, Butler RN, Howarth GS. Orally administered emu oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis. Br J Nutr. 2010;104:513–519.PubMedCrossRef
18.
go back to reference Geier MS, Butler RN, Giffard PM, Howarth GS. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. Int J Food Microbiol. 2007;114:267–274.PubMedCrossRef Geier MS, Butler RN, Giffard PM, Howarth GS. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. Int J Food Microbiol. 2007;114:267–274.PubMedCrossRef
19.
go back to reference Tomas FM, Knowles SE, Owens PC, et al. Effects of full-length and truncated insulin-like growth factor-i on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats. J Endocrinol. 1991;128:97–105.PubMedCrossRef Tomas FM, Knowles SE, Owens PC, et al. Effects of full-length and truncated insulin-like growth factor-i on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats. J Endocrinol. 1991;128:97–105.PubMedCrossRef
20.
go back to reference Portolesi R, Powell BC, Gibson RA. Competition between 24:5n–3 and ala for delta 6 desaturase may limit the accumulation of DHA in HepG2 cell membranes. J Lipid Res. 2007;48:1592–1598.PubMedCrossRef Portolesi R, Powell BC, Gibson RA. Competition between 24:5n–3 and ala for delta 6 desaturase may limit the accumulation of DHA in HepG2 cell membranes. J Lipid Res. 2007;48:1592–1598.PubMedCrossRef
21.
go back to reference Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993;38:1722–1734.PubMedCrossRef Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993;38:1722–1734.PubMedCrossRef
22.
go back to reference Howarth GS, Xian CJ, Read LC. Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-i for twenty weeks in a rat model of chronic inflammatory bowel disease. Growth Factors. 2000;18:119–133.PubMedCrossRef Howarth GS, Xian CJ, Read LC. Predisposition to colonic dysplasia is unaffected by continuous administration of insulin-like growth factor-i for twenty weeks in a rat model of chronic inflammatory bowel disease. Growth Factors. 2000;18:119–133.PubMedCrossRef
23.
go back to reference Pelton NC, Tivey D, Howarth GS, Davidson GP, Butler RN. A novel breath test for the non-invasive assessment of small intestinal mucosal injury following methotrexate administration in the rat. Scand J Gastroenterol. 2004;39:1015–1016.PubMedCrossRef Pelton NC, Tivey D, Howarth GS, Davidson GP, Butler RN. A novel breath test for the non-invasive assessment of small intestinal mucosal injury following methotrexate administration in the rat. Scand J Gastroenterol. 2004;39:1015–1016.PubMedCrossRef
24.
go back to reference Tooley KL, Howarth GS, Butler RN. Mucositis and non-invasive markers of small intestinal function. Cancer Biol Ther. 2009;8:753–758.PubMed Tooley KL, Howarth GS, Butler RN. Mucositis and non-invasive markers of small intestinal function. Cancer Biol Ther. 2009;8:753–758.PubMed
25.
go back to reference Yazbeck R, Howarth GS, Geier MS, Demuth HU, Abbott CA. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci. 2008;13:6850–6858.PubMedCrossRef Yazbeck R, Howarth GS, Geier MS, Demuth HU, Abbott CA. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci. 2008;13:6850–6858.PubMedCrossRef
26.
go back to reference Vowinkel T, Kalogeris T, Mori M, Krieglstein CF, Granger DN. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 2004;49:556–564.PubMedCrossRef Vowinkel T, Kalogeris T, Mori M, Krieglstein CF, Granger DN. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 2004;49:556–564.PubMedCrossRef
27.
go back to reference Gaudio E, Taddei G, Vetuschi A, et al. Dextran sulfate sodium (DSS) colitis in rats: Clinical, structural, and ultrastructural aspects. Dig Dis Sci. 1999;44:1458–1475.PubMedCrossRef Gaudio E, Taddei G, Vetuschi A, et al. Dextran sulfate sodium (DSS) colitis in rats: Clinical, structural, and ultrastructural aspects. Dig Dis Sci. 1999;44:1458–1475.PubMedCrossRef
28.
go back to reference Drozdowski L, Thomson AB. Intestinal mucosal adaptation. World J Gastroenterol. 2006;12:4614–4627.PubMed Drozdowski L, Thomson AB. Intestinal mucosal adaptation. World J Gastroenterol. 2006;12:4614–4627.PubMed
29.
go back to reference Deschner EE, Maskens AP. Significance of the labeling index and labeling distribution as kinetic parameters in colorectal mucosa of cancer patients and DMH treated animals. Cancer. 1982;50:1136–1141.PubMedCrossRef Deschner EE, Maskens AP. Significance of the labeling index and labeling distribution as kinetic parameters in colorectal mucosa of cancer patients and DMH treated animals. Cancer. 1982;50:1136–1141.PubMedCrossRef
30.
go back to reference Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet. 1980;2:712–715.PubMedCrossRef Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet. 1980;2:712–715.PubMedCrossRef
31.
go back to reference Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci. 1991;36:185–187.PubMedCrossRef Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci. 1991;36:185–187.PubMedCrossRef
32.
go back to reference Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med. 1989;320:23–28.PubMedCrossRef Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med. 1989;320:23–28.PubMedCrossRef
33.
go back to reference Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:285–290.PubMedCrossRef Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:285–290.PubMedCrossRef
34.
go back to reference Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW. Characterisation of acute murine dextran sodium sulphate colitis: Cytokine profile and dose dependency. Digestion. 2000;62:240–248.PubMedCrossRef Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW. Characterisation of acute murine dextran sodium sulphate colitis: Cytokine profile and dose dependency. Digestion. 2000;62:240–248.PubMedCrossRef
Metadata
Title
Emu Oil Increases Colonic Crypt Depth in a Rat Model of Ulcerative Colitis
Authors
Suzanne M. Abimosleh
Ruth J. Lindsay
Ross N. Butler
Adrian G. Cummins
Gordon S. Howarth
Publication date
01-04-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1979-1

Other articles of this Issue 4/2012

Digestive Diseases and Sciences 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.